(Total Views: 452)
Posted On: 09/04/2021 1:17:06 PM
Post# of 155036
Good on you.
"The incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab."
Read More: https://investorshangout.com/post/view?id=623...z75Vz6GDnt
That oddly underwhelming fact was not overlooked by Kelly, Recknor, et al.
That fact once properly pondered for all its profoundly positive implications, is just stunning in both its simplicity and importance to all of medicine. However inadvertent the route to this day and the uncovering of LL's potency along the way - those here - are now in the catbird seat of all LL's amazing implications. Hang tight. Stay put.
"The incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab."
Read More: https://investorshangout.com/post/view?id=623...z75Vz6GDnt
That oddly underwhelming fact was not overlooked by Kelly, Recknor, et al.
That fact once properly pondered for all its profoundly positive implications, is just stunning in both its simplicity and importance to all of medicine. However inadvertent the route to this day and the uncovering of LL's potency along the way - those here - are now in the catbird seat of all LL's amazing implications. Hang tight. Stay put.
(5)
(0)
